Work

Immunotherapy for hormone receptor‒positive HER2-negative breast cancer

Year: 2024

Type: review

Abstract: Additional therapies are needed to improve outcomes in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer. Research on the potential role of immunotherapy, particularly programmed cell death protein 1/programmed cell death ligand 1 inhibitors, is rapidly expanding in both the early and metastatic settings with some preliminary evidence suggesting benefit when used as part of combination therapy. Several ongoing phase 3 studies should help define their future role in treating these patients.

Source: npj Breast Cancer

DOI: 10.1038/s41523-024-00704-9

Authors: Fatima Cardoso, Kim M. Hirshfield, Kimberly A. Kraynyak, Konstantinos Tryfonidis, Aditya Bardia

Institutions: Champalimaud Foundation, Centro Champalimaud, Merck & Co., Inc., Rahway, NJ, USA (United States), University of California, Los Angeles, UCLA Jonsson Comprehensive Cancer Center

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,490